8-K filing — Opus Genetics, Inc. (IRD)
Filed: 2026-09-11 AccNo: 0001140361-26-036277 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Opus Genetics Announces Results From Low-Dose Cohort 1 Of BIRD-1, Ongoing Phase 1/2 Clinical Trial Evaluating Opgx-BEST1 Showing Favorable Safety, Tolerability Profile With No Serious Adverse Events Or Dose-Limiting Toxicities Observed
OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13
Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.
Oppenheimer Maintains Outperform on Opus Genetics, Raises Price Target to $20
Oppenheimer analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $20.
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $8 price target.